NCT01899859View on ClinicalTrials.gov

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
DRUG

GR-MD-02

GR-MD-02; galactoarabino-rhamnogalaturonate

DRUG

Placebo

GR-MD-02 Placebo

Trial Locations (1)

78234

Brooke Army Medical Ctr., San Antonio

Sponsors
All Listed Sponsors
lead

Galectin Therapeutics Inc.

INDUSTRY